Esketamine (Spravato™): a ne...
By: Sylvia Hong (PharmD Candidate c/o 2021), Muaz Sadeia (PharmD Candidate c/o 2021) On March 5, 2019, Janssen Pharmaceuticals gained approval from the Food and Drug Administration (FDA) for esketamine (Spravato™), the first fast acting nasal spray antidepressant indicated for treatment of resistant depression as conjunctive therapy to oral antidepressants in adults.1 This new…